Most recently, Dr. Marantz served as the executive vice president and chief business officer at Krystal Biotech. Additionally, she currently serves on the board of Arcturus Therapeutics, according to a Nov. 9 Scholar Rock news release.
“I look forward to overseeing future clinical development, including the Phase 1 DRAGON proof-of-concept trial of SRK-181 in patients with advanced cancer, and progressing the Phase 3 SAPPHIRE trial of apitegromab for the treatment of SMA towards potential regulatory approval,” Dr. Marantz said.
